Interpretation of the assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A position paper from ESC/EHRA/AACA/APHRS
- VernacularTitle:《2022 ESC/EHRA/AACA/APHRS意见书：评估与减轻心房颤动和静脉血栓栓塞出血风险》要点解读
- Author:
Chong LUO
1
;
Longrong BIAN
1
;
Zhong WU
1
Author Information
1. Department of Cardiovascular Surgery, West China Hospital, Sichuan University, Chengdu, 610041, P. R. China
- Publication Type:Journal Article
- Keywords:
Atrial fibrillation;
oral anticoagulants;
drug-related bleeding;
position paper interpretation
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2022;29(07):812-819
- CountryChina
- Language:Chinese
-
Abstract:
Atrial fibrillation is now the most frequent kind of adult arrhythmia in the world, with a prevalence rate at 2%-4%. In addition to the clinical symptoms of palpitation, shortness of breath, chest tightness, and decreased exercise tolerance, patients with atrial fibrillation have a 4 to 5 times higher risk of ischemic stroke than patients without atrial fibrillation, so anticoagulation therapy should be tailored to the CHA2DS2-VASc [congestive heart failure, hypertension, age≥75 years (doubled), diabetes mellitus, stroke (doubled)-vascular disease, age 65-74 years and sex category (female)] score. Oral anticoagulants not only prevent thrombosis, but also raise the risk of drug-related bleeding. This paper examines the assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A position paper from ESC/EHRA/AACA/APHRS, in order to provide readers with the most up-to-date research on anticoagulant bleeding risk management in patients with atrial fibrillation.
